Biden spent like no president in history, and, with a sleight of hand, by taking hundreds of billions out of Medicare and spending it on green energy subsidies.

Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price negotiations, federal health officials announced Friday. The negotiations for the 15 additional drugs, which will be handled by the incoming administration, assure major savings for Americans.

Biden's administration announced weight loss drugs Ozempic and Wegovy will be included on Medicare's list of medications subject to direct price negotiations.

Reforms of prescription drug pricing are finally taking full effect, just in time for Donald Trump and the Republicans to wreck them.

If public opinion polls are the guide, Joe Biden has been the worst president since Richard Nixon. Here's why that may be true.

The list includes Novo Nordisk’s blockbuster diabetes injection Ozempic, weight loss shot Wegovy and diabetes pill Rybelsus, which are considered one product.

The AARP report suggests the spending cap could be huge for Medicare enrollees who take costly drugs for cancer, rheumatoid arthritis, and other conditions.

The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manuf

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be targeted under legislation that’s expected save the government more than $200 billion over a decade.

Stock prices for Novo Nordisk dropped precipitously Friday after a last-minute announcement from the Biden administration that the premier drugs from the Danish pharmaceutical juggernaut have been selected for forced price negotiations for Medicare.